These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25870264)

  • 1. Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition.
    Leight JL; Tokuda EY; Jones CE; Lin AJ; Anseth KS
    Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5366-71. PubMed ID: 25870264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
    Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
    Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
    Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
    Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
    Pal HC; Diamond AC; Strickland LR; Kappes JC; Katiyar SK; Elmets CA; Athar M; Afaq F
    Oncotarget; 2016 Jan; 7(2):1227-41. PubMed ID: 26517521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLX4032: does it keep its promise for metastatic melanoma treatment?
    Livingstone E; Zimmer L; Piel S; Schadendorf D
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1439-49. PubMed ID: 20942773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
    Di Michele M; Stes E; Vandermarliere E; Arora R; Astorga-Wells J; Vandenbussche J; van Heerde E; Zubarev R; Bonnet P; Linders JT; Jacoby E; Brehmer D; Martens L; Gevaert K
    J Proteome Res; 2015 Oct; 14(10):4179-93. PubMed ID: 26293246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of superoxide and nitric oxide in BRAF(V600E) inhibitor PLX4032-induced growth inhibition of melanoma cells.
    Yu L; Gao LX; Ma XQ; Hu FX; Li CM; Lu Z
    Integr Biol (Camb); 2014 Dec; 6(12):1211-7. PubMed ID: 25363644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
    Botton T; Yeh I; Nelson T; Vemula SS; Sparatta A; Garrido MC; Allegra M; Rocchi S; Bahadoran P; McCalmont TH; LeBoit PE; Burton EA; Bollag G; Ballotti R; Bastian BC
    Pigment Cell Melanoma Res; 2013 Nov; 26(6):845-51. PubMed ID: 23890088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-β1 and TNF-α differentially regulate Twist1 mediated resistance towards BRAF/MEK inhibition in melanoma.
    Menon DR; Wels C; Bonyadi Rad E; Joshi S; Knausz H; Lade-Keller J; Brandner JM; Schaider H
    Pigment Cell Melanoma Res; 2013 Nov; 26(6):912-6. PubMed ID: 23848983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
    Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
    Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
    Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
    Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Berberine Inhibits Human Melanoma A375.S2 Cell Migration and Invasion via Affecting the FAK, uPA, and NF-κB Signaling Pathways and Inhibits PLX4032 Resistant A375.S2 Cell Migration In Vitro.
    Liu JF; Lai KC; Peng SF; Maraming P; Huang YP; Huang AC; Chueh FS; Huang WW; Chung JG
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30104528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
    Bahadoran P; Allegra M; Le Duff F; Long-Mira E; Hofman P; Giacchero D; Passeron T; Lacour JP; Ballotti R
    J Clin Oncol; 2013 Jul; 31(19):e324-6. PubMed ID: 23715574
    [No Abstract]   [Full Text] [Related]  

  • 18. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
    Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
    Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
    Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
    Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness.
    Tokuda EY; Leight JL; Anseth KS
    Biomaterials; 2014 May; 35(14):4310-8. PubMed ID: 24565518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.